Ganti, A. K., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Dib, E. G., Duvivier, H., … Schilsky, R. L. (2022). 978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In Annals of Oncology (Vol. 33, pp. S997–S998). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.1106

Ganti, A. K., M. Rothe, P. K. Mangat, E. Garrett-Mayer, E. G. Dib, H. Duvivier, E. Ahn, et al. “978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In Annals of Oncology, 33:S997–98. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.1106.

Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier H, et al. 978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: Annals of Oncology. Elsevier BV; 2022. p. S997–8.

Ganti, A. K., et al. “978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S997–98. Crossref, doi:10.1016/j.annonc.2022.07.1106.

Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier H, Ahn E, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, O’Lone R, Grantham GN, Halabi S, Schilsky RL. 978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Annals of Oncology. Elsevier BV; 2022. p. S997–S998.